PureTech’s deupirfenidone shows strong and durable efficacy

UK-based PureTech Health (LSE: PRTC) delivered a late-breaking, oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco.

The presentation provided further insights into the successful Phase II ELEVATE IPF trial of deupirfenidone (LYT-100), highlighting the strength and durability of deupirfenidone’s treatment effect through at least 52 weeks while maintaining favorable tolerability in patients living with idiopathic pulmonary fibrosis (IPF).

“The ELEVATE IPF trial is one of the most promising Phase II studies we’ve seen in IPF in recent years,” said Dr Toby Maher, professor of medicine and director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles, and lead investigator in the ELEVATE IPF trial. “The ability for a monotherapy to reduce lung function decline close to a level seen in healthy older adults, and to sustain that effect over time without compromising tolerability, is not something we have seen with currently available therapies. Deupirfenidone has the potential to raise the bar for what patients and physicians can expect from IPF treatment,” he added.